David Siegel D, Oriol A, Rajnics P. et al. Updated results from ASPIRE and ENDEAVOR, randomised, open-label multicentre phase 3 studies of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM). EHA 2017, abstract P333.
Nieuwe data emicizumab (Hemlibra®) bij chirurgische ingrepen bevestigen eerdere bevindingen
aug 2019 | Benigne hematologie